About Us

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such asautoimmune diseases. We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The ideas that we choose are based on solid scientific grounds, where we, with reasonable assumptions, can understand the underlying biology, clinical relevance and patient benefit. The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion runs its development programs in a partly virtual organization in close collaboration with selected partners with specific expertise in drug development. AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com

Subscribe